Patents Assigned to Io Therapeutics, Inc.
  • RXR agonist salt form, polymorphs thereof, and uses thereof
    Patent number: 11919848
    Abstract: Provided herein are salt and solid forms of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid, including a Tris salt form of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid, and polymorphs thereof, methods of preparing the compounds, and their uses.
    Type: Grant
    Filed: March 14, 2023
    Date of Patent: March 5, 2024
    Assignee: Io Therapeutics, Inc.
    Inventors: Vidyasagar Vuligonda, Martin E. Sanders, Shanming Kuang, Harsh Shailesh Shah
  • Use of an RXR agonist and taxanes in treating Her2+ cancers
    Patent number: 11896558
    Abstract: The present specification provides improved methods of treating Her2+ cancers in which an RXR agonist and a taxane are administered to a subject having a Her2+ cancer. Thyroid hormone and other anticancer agents may also be administered. Related compositions and combination are also disclosed.
    Type: Grant
    Filed: December 7, 2022
    Date of Patent: February 13, 2024
    Assignees: Io Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
  • Methods of using RAR? agonists for cancer treatment
    Patent number: 11793835
    Abstract: The invention discloses novel RAR gamma selective agonists used in the treatment of cancer. The invention also discloses administration of RAR gamma selective agonists to mammals, including humans for the purpose of selectively activating RAR gamma receptor and treat cancer by way of activating tumor infiltrating lymphocytes.
    Type: Grant
    Filed: November 23, 2022
    Date of Patent: October 24, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Martin E. Sanders, Vidyasagar Vuligonda
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 11793781
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: October 24, 2023
    Assignees: Io Therapeutics, Inc., Trustees of Dartmouth College
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • RAR selective agonists in combination with immune modulators for cancer immunotherapy
    Patent number: 11786555
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: October 17, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 11779558
    Abstract: Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: October 10, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 11737996
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: August 29, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
    Patent number: 11690831
    Abstract: The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: July 4, 2023
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
    Patent number: 11648222
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: May 16, 2023
    Assignees: IO Therapeutics, Inc., The Johns Hopkins Univercity
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 11648223
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: May 16, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 11576881
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: February 14, 2023
    Assignees: Io Therapeutics, Inc., Trustees of Dartmouth College
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 11547684
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: January 10, 2023
    Assignees: Io Therapeutics, Inc., Trustees of Dartmouth College
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Treatment of disease with esters of selective RXR agonists
    Patent number: 11517549
    Abstract: The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone. The esters of an RXR agonist can be useful in the treatment of cancer, nervous system, autoimmune, and muscular disorders.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: December 6, 2022
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 11246845
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: February 15, 2022
    Assignees: Io Therapeutics, Inc., Trustees of Dartmouth College
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Use of an RXR agonist in treating HER2+ cancers
    Patent number: 11224583
    Abstract: The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: January 18, 2022
    Assignee: Io Therapeutics, Inc.
    Inventors: Martin E. Sanders, Powel H. Brown
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 11166927
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: November 9, 2021
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 11065219
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: July 20, 2021
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 10987330
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: April 27, 2021
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 10980760
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: April 20, 2021
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 10980761
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: April 20, 2021
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders